Unity Biotechnology, Inc. (UBX)

Market Cap	19.71M
Revenue (ttm)	n/a
Net Income (ttm)	-21.89M
Shares Out	16.85M
EPS (ttm)	-1.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	52,827
Open	1.170
Previous Close	1.160
Day's Range	1.140 - 1.180
52-Week Range	1.105 - 2.170
Beta	0.83
Analysts	Strong Buy
Price Target	8.00 (+583.76%)
Earnings Date	Nov 4, 2024

About UBX

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company’s lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for th...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 3, 2018
• Employees: 19
• Stock Exchange: NASDAQ
• Ticker Symbol: UBX
• Website: https://unitybiotechnology.com

Analyst Forecast

According to 2 analysts, the average rating for UBX stock is "Strong Buy." The 12-month stock price forecast is $8.0, which is an increase of 583.76% from the latest price.

Price Target

$8.0

(583.76% upside)

Analyst Consensus: Strong Buy